Blogs
Why are eCOA studies still so challenging? And, how can we make them better?
June 3, 2026
Florence Mowlem, PhD, uMotif’s Chief Scientific Officer, breaks down the top challenges and offers practical solutions to help sponsors, CROs, and technology providers work together more effectively.
18 months of FDA’s Core Patient-Reported Outcomes in Cancer Clinical Trials Guidance – have we seen its impact?
May 26, 2026
uMotif’s Florence Mowlem, PhD, Chief Scientific Officer, explores the FDA’s evolving push for patient-reported outcomes in oncology clinical trials and what it means for the future of drug development.
eCOA User Acceptance Testing (UAT): Recommendations for Clinical Trial Success
April 27, 2026
Read what uMotif believes a successful UAT starts with, in this blog written by Julia Lakeland, Chief Customer Success Officer.
Better Experience, Better Evidence: How Human-centered Design Changes Clinical Trials
April 14, 2026
uMotif’s co-founders, Bruce Hellman and Ben James, share how human-centered design in clinical trials looks like in practice and how it can change the patient experience and data quality.
Clinical Trials Are All About the Data: Why Ensuring eCOA Stakeholder Alignment Is Critical
March 13, 2026
uMotif’s Steve Lyons explores why clear stakeholder alignment among sponsors, CROs, and eCOA vendors is critical to effective data management across the full lifecycle of a clinical trial.
Partners for Success: Governance Best Practices to Streamline eCOA Trial Launch
November 21, 2025
Rhiannon Hyde, Director, Governance and Transformation, shares uMotif’s governance approach and how they drive success for clients.
Humans and AI share the spotlight at SCDM
October 6, 2025
Our Chief Patient Officer & Co-Founder, Bruce Hellman shares his takeaways from the 2025 Society for Clinical Data Managers (SCDM) Conference.
Three questions (+) with Steve Lyons
September 30, 2025
uMotif’s VP of Data Delivery and Integration Engineering Steve Lyons discusses how data delivery and integration strategy powers our customer centric mission, which technology innovations are on Steve’s radar for the year ahead, and more.
Applying the Scientific Lens to Clinical Research Technology: The Chief Scientific Officer Perspective
September 24, 2025
Reflecting on her first year as CSO at uMotif, Florence Mowlem, PhD, explores the evolving role of scientific leadership tech.
Three questions with Julia Lakeland
August 7, 2025
Our Chief Customer Success Officer, Julia Lakeland shares her vision for redefining customer success through user-centric, data-driven solutions that streamline clinical trial delivery.
The uMotif Care Cluster Solution: Capturing Quality Data from Participants & Their Caregivers
June 26, 2025
uMotif’s Florence Mowlem, PhD, shares the problems Care Cluster solves and the opportunities it creates for participants, caregivers, and trial sponsors in their data collection.
How to build strong technology vendor and CRO partnerships that deliver for patients, sites, and sponsors
March 31, 2025
Hear from uMotif’s Chief Patient Officer and Co-Founder, Bruce Hellman, as he discusses the need for collaboration among vendors to successfully navigate the complexities of clinical trials.
Three questions (+) with Florence Mowlem
November 25, 2024
In the latest installment of our “Three questions with” series, uMotif Chief Scientific Officer Florence Mowlem, PHD shares her deep experience in providing scientific guidance in the development of eCOA/ePRO software, discusses challenges facing sponsors in adopting digital health technologies, and what excites her about the direction of patient-focused software.
SCDM 2024 – Opportunities and optimism abound for making clinical trials more patient- and site-centric
October 10, 2024
uMotif’s Bruce Hellman, just back from #SCDM, shares 3 key takeaways from the event—including powerful opportunities for making clinical trials more patient- and site-centric.
Three questions (+) with Steve Rosenberg
November 15, 2023
Hear from our Chief Executive Officer, Steve Rosenberg as he shares insights on the current eCOA/ePRO landscape—both adoption and competition—as well as how modern eCOA/ePRO systems must deliver an exceptional user experience to patients as well as sites.
My Take: Three biggest themes of the 2023 clinical trial conference season.
March 19, 2023
The Fall conference season is a wrap, and uMotif Chief Patient Officer/Co-founder Bruce Hellman shares his take on the three biggest themes resonating across the events. Read the blog to see if your list matches his.
Modern eCOA/ePRO: A people-first approach paves the way for better data collection
October 17, 2023
Chief Patient Officer and Co-founder, Bruce Hellman, discusses how modern eCOA/ePRO systems can pave the way for better, human-centric data collection.
SCDM 2023 – patient-centricity in clinical data management
October 19, 2023
In our latest blog, uMotif’s Chief Patient Officer and Co-founder, Bruce Hellman discusses his takeaways from his recent trip to San Diego for the 2023 Society of Clinical Data Managers (SDCM) 25th anniversary conference.
Pfizer’s initiative to return clinical trial data to patients recognizes participant contributions and sets the pace for the industry
October 5, 2023
uMotif’s Chief Patient Officer/ Co-founder, Bruce Hellman celebrates Pfizer’s decision to return individual clinical trial data to patients at scale – in an easy-to-understand format – and explores the impact of expanding data return to real time, when feasible.
What does it take to be a modern eCOA/ePRO platform?
August 6, 2023
uMotif’s Chief Product Officer, Julia Lakeland shares her knowledge on the qualities that define and distinguish modern eCOA/ePRO, and why they matter to sponsors, CROs, clinical trial sites, and most importantly patients.
Three questions with Ben James
July 14, 2023
As we continue our ‘Three Questions with’ series, uMotif’s Chief Design Officer and Co-founder provides insight into the importance of prioritizing human-centricity in the design of modern eCOA/ePRO platforms and shares his thoughts on the future growth of eCOA/ePRO.
OurBrainBank (OBB) to improve the quality of life for glioblastoma patients
July 20, 2023
Glioblastoma Multiforme (GBM) is the most invasive and lethal type of brain cancer. uMotif is honored to have known and collaborated with the Glioblastoma charity, Our Brain Bank and Founder, Jessica Morris – in her quest to improve and extend the lives of those with GBM.
Three questions with Bruce Hellman
June 21, 2023
uMotif’s Chief Patient Officer and Co-founder shares our vision for giving patients the best experience possible and provides insights into how sponsors and CROs can transform study protocols and the participant experience with ePRO/eCOA.
100 for Parkinson’s study
April 24, 2023
This study was designed to help participants learn more about their own health, better understand how technology can support people living with Parkinson’s, and build a research dataset to drive new insights.
Guidance on Use of Patient Experience Data in Real World studies – EU Perspectives
April 24, 2023
Patient insights are expected to become increasingly instrumental in optimising medicine development and regulatory decision making.
uMotif eCOA/ePRO Platform Helps to Expand Understanding of Hypoglycaemic Events
April 24, 2023
Patient engagement expert and uMotif sales leader Peter Robinson shares insight at the 2023 International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) – Feb. 22-25, Berlin.
CNS Summit 2022 Boca was buzzing with patient-centricity
April 24, 2023
Our Chief Patient Office Bruce Hellman attended the CNS Summit held in Boca Raton, Florida and discovered that true patient centricity is the way forward for patient trials.
ISPOR 2022 – The continued rise of the Patient Reported Outcome
April 24, 2023
Bruce Hellman Chief Patient Officer reflects on his key learnings from this year’s ISPOR assembly on the future of the life sciences industry.
Digital Era Expands Scope and Impact for Medical Affairs. Prepare to Rise to the Challenge
April 24, 2023
With the rise of digital technology expanding the role of Medical Affairs, our Chief Product Officer, Julia Lakeland explains how Medical Affairs has a critical role to play in serving as the bridge between patients and pharmaceutical companies to ensure patient safety and improve outcomes.
Three things I learned at the PCMG 2022 assembly – “ The ‘I’ of the Storm”
April 24, 2023
Bruce Hellman reflects on his time at the Pharmaceutical Contract Management Group annual assembly, highlighting key themes from the conference.
